Chicago Prostate Center : News Releases

Free Prostate Screening for Prostate Cancer Awareness Month

Fri, 17 Sep 2010 00:00:00 -0400

Come to Chicago Prostate Center to get a free prostate screening on Friday, September 17, 2010. Please call 630-654-2515 for an appointment.

Also meet comedian Tom Dreesen! A Chicago native and avid supporter of prostate cancer awareness, Tom will be available for a meet and greet at Chicago Prostate Center on Friday, September 17.

Young Men Have Equivalent Biochemical Outcomes Compared With Older Men After Treatment With Brachytherapy for Prostate Cancer

Wed, 13 Jan 2010 00:00:00 -0500

Young Men Have Equivalent Biochemical Outcomes Compared With Older Men After Treatment With Brachytherapy for Prostate Cancer.
Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG.

Department of Radiation Oncology Memorial Sloan-Kettering Cancer Center, New York, New York.

PURPOSE: To evaluate retrospectively the biochemical outcomes of young men treated with low-dose-rate brachytherapy for prostate cancer. METHODS AND MATERIALS: From 1990 to 2005, 1,665 men with clinically localized prostate cancer were treated with low-dose-rate brachytherapy +/- hormone therapy (HT) +/- external beam radiotherapy and underwent >/=2 years of follow-up. Patients were stratified on the basis of age: </=60 (n = 378) and >60 years (n = 1,287). Biochemical failure was defined as a prostate-specific antigen (PSA) nadir plus 2 ng/mL. Univariate and multivariate analyses were used to determine the association of variables with freedom from biochemical failure (FFbF). RESULTS: Median follow-up was 68 months (range, 24-180) for men </=60 years and 66 months (range, 24-200) for men >60. For the entire group, the actuarial 5- and 8-year FFbF rates were 94% and 88%, respectively. Men </=60 demonstrated similar 5- and 8-year FFbF (95% and 92%) compared with men >60 (93% and 87%; p = 0.071). A larger percent of young patients presented with low-risk disease; lower clinical stage, Gleason score (GS), and pretreatment PSA values; were treated after 1997; did not receive any HT; and had a high biologic effective dose (BED) of radiation (all ps <0.001). On multivariate analysis, PSA (p = 0.001), GS (p = 0.005), and BED (p < 0.001) were significantly associated with FFbF, but age was not (p = 0.665). CONCLUSION: Young men achieve excellent 5- and 8-year biochemical control rates that are comparable to those of older men after prostate brachytherapy. Young age should not be a deterrent when considering brachytherapy as a primary treatment option for clinically localized prostate cancer. Copyright © 2009 Elsevier Inc. All rights reserved.

PMID: 20044216 [PubMed – as supplied by publisher]

Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study

Tue, 12 Jan 2010 00:00:00 -0500

Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study

2 Independent Studies Released on the Effectiveness of Prostate Cancer Treatment